Connection
Frederick Masoudi to Eligibility Determination
This is a "connection" page, showing publications Frederick Masoudi has written about Eligibility Determination.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.081 |
|
|
|
-
Hess PL, Kennedy K, Cowherd M, Virani SS, Masoudi FA, Navar AM, Yeh RW, Ho PM, Maddox TM. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. Am Heart J. 2018 01; 195:151-152.
Score: 0.032
-
Gehi AK, O'Brien E, Pathak RK, Sanders P, Kennedy KF, Virani SS, Masoudi FA, Maddox TM. Implications of the LEGACY trial on US Atrial Fibrillation Patients: An NCDR Research to Practice (R2P) Project. Am J Cardiol. 2017 02 15; 119(4):579-584.
Score: 0.030
-
Daugherty SL, Peterson PN, Wang Y, Curtis JP, Heidenreich PA, Lindenfeld J, Vidaillet HJ, Masoudi FA. Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria? Am Heart J. 2009 Aug; 158(2):224-9.
Score: 0.018